Literature DB >> 18084257

Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors.

Sohei Yamamoto1, Hitoshi Tsuda, Masashi Takano, Tsunekazu Kita, Kazuya Kudoh, Kenichi Furuya, Seiichi Tamai, Osamu Matsubara.   

Abstract

Recent studies have shown that platelet-derived growth factors and their receptors are frequently co-expressed in ovarian cancers. Herein, we investigated the role of the platelet-derived growth factor pathway in the development of ovarian clear-cell adenocarcinoma, a highly chemoresistant form of ovarian cancer. Immunohistochemical expression of platelet-derived growth factor receptor-alpha and receptor-beta, platelet-derived growth factor A-chain and B-chain was examined in 31 cases of clear-cell adenocarcinoma and 56 coexisting putative precursor lesions: 17 non-atypical and 19 atypical endometrioses, and 10 non-atypical and 10 atypical clear-cell adenofibroma components. Twenty-one solitary endometrioses were also examined. Vascular endothelial cells were always positive for all the markers examined, and were used as positive controls. The frequencies of positivity for platelet-derived growth factor receptor-alpha and receptor-beta, and platelet-derived growth factor A-chain increased in accordance with higher cytologic atypia in the putative precursors: 71, 47, and 59% in the 17 non-atypical endometrioses, 84, 73, and 84% in the 19 atypical endometrioses, 0% each in the 10 non-atypical clear-cell adenofibromas, 100, 90, and 90% in the 10 atypical clear-cell adenofibromas, and 97, 97, and 100% in the 31 clear-cell adenocarcinomas, respectively. Positivity for platelet-derived growth factor B-chain increased in accordance with increased atypia in clear-cell adenofibroma: 0% in non-atypical clear-cell adenofibromas, 30% in atypical clear-cell adenofibromas, and 60% in coexisting carcinomas. However, in contrast, positivity for platelet-derived growth factor B-chain decreased in accordance with increased atypia in endometriosis coexisting with clear-cell adenocarcinomas: 35% in non-atypical endometrioses, 11% in atypical endometrioses, and 5% in coexisting carcinomas. Platelet-derived growth factor receptor-alpha and receptor-beta, and their ligands A-chain and B-chain were positive in 14, 29, 19, and 62% of the solitary endometrioses, respectively. These results indicate activation of the platelet-derived growth factor pathway in ovarian clear-cell adenocarcinomas and suggest biological differences between carcinomas that arise in association with clear-cell adenofibroma vs endometriosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18084257     DOI: 10.1038/modpathol.3800984

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  12 in total

1.  Identification of multiple pathways involved in the malignant transformation of endometriosis (Review).

Authors:  Yumi Higashiura; Hirotaka Kajihara; Hiroshi Shigetomi; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2012-04-23       Impact factor: 2.967

2.  Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.

Authors:  Hiroshi Kobayashi; Hitomi Sugimoto; Shunsuke Onishi; Kazutoshi Nakano
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

3.  PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2011-11-26       Impact factor: 4.064

4.  Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer.

Authors:  Anca Maria Cimpean; Ionut Marcel Cobec; Raluca Amalia Ceaușu; Roxana Popescu; Anca Tudor; Marius Raica
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

5.  An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Kozue Suzuki; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2009-08-05       Impact factor: 4.064

6.  Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Kosuke Miyai; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2009-10-24       Impact factor: 4.064

Review 7.  Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management.

Authors:  Masaki Mandai; Ken Yamaguchi; Noriomi Matsumura; Tsukasa Baba; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

8.  Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review.

Authors:  Holly Butler; Omar Saulat; Barbara-Ann Guinn
Journal:  Carcinogenesis       Date:  2022-04-25       Impact factor: 4.741

9.  Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up.

Authors:  Christine Vestergaard Madsen; Karina Dahl Steffensen; Marianne Waldstrøm; Anders Jakobsen
Journal:  Patholog Res Int       Date:  2012-09-23

10.  BMP-specific SMADs function as novel repressors of PDGFA and modulate its expression in ovarian granulosa cells and tumors.

Authors:  S K Tripurani; R W Cook; K W Eldin; S A Pangas
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.